Evidence map›Paper›PMID 38107020›Full record

ArticleBrain, behavior, & immunity - health2024

SARS-CoV-2 infection and cognition in community-dwelling and nursing home residents in southern Switzerland.

Greta Rizzi, Deborah Pacifico, Serena Sabatini, Anna Maria Annoni, Federico Mele, Sandra Jovic, Luca Piccoli, Laurie Corna, Rebecca Amati, William Pertoldi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Brain, behavior, & immunity - health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Cognition and Long COVID: a Review.Current neurology and neuroscience reports · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Greta RizziInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Deborah PacificoInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Serena SabatiniInstitute of Mental Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Anna Maria AnnoniInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Federico MeleInstitute for Research in Biomedicine, Università Della Svizzera Italiana, Bellinzona, Switzerland.
Sandra JovicInstitute for Research in Biomedicine, Università Della Svizzera Italiana, Bellinzona, Switzerland.
Luca PiccoliHumabs BioMed SA, a Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Laurie CornaCentre of Competence on Ageing, Department of Business Economics, Health & Social Care, University of Applied Sciences & Arts of Southern Switzerland, Manno, Switzerland.
Rebecca AmatiInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
William PertoldiIstituti Sociali, Chiasso, Switzerland.
Maddalena FiordelliInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Federica SallustoInstitute for Research in Biomedicine, Università Della Svizzera Italiana, Bellinzona, Switzerland.
Emiliano AlbaneseInstitute of Public Health, Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
Università della Svizzera italiana · CHETH Zurich · CHUniversity of Applied Sciences and Arts of Southern Switzerland · CHUniversity of Nottingham · GBVir Biotechnology (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 patients can report 'brain fog' and may exhibit cognitive symptoms for months after recovery (Cognitive COVID). However, evidence on whether and the extent to which SARS-CoV-2 infection impacts cognition irrespective of COVID-19 course and severity is limited to clinical samples and mainly comes from prognostic studies. We aimed to explore the association between serologically confirmed SARS-CoV-2 infection and cognitive functioning in community-based and institutionalized older adults, irrespective of COVID-19 symptoms. Methods: We conducted a case-control study nested into two cohorts in Southern Switzerland. Eligible subjects were Italian speaking older adults, without a previous diagnosis of dementia, who underwent serological testing for anti-SARS-CoV-2 antibodies between November 2020 and July 2021. We manually selected age-, sex- and education-matched cases (i.e., individuals with a serologically confirmed SARS-CoV-2 infection), with seronegative controls, and we conducted in-person neuropsychological assessments using validated, highly sensitive cognitive tests. Results: We completed 38 neuropsychological assessments in a mostly female sample of older adults (Mean age: 83.13 ± 8.95; 86.8% women). 17 were community dwelling individuals while 21 lived in a nursing home. As expected, socio-demographic characteristics of age, gender and educational level were similarly distributed between cases (n = 14) and controls (n = 24). In linear regression models, cases had significantly lower scores in cognitive tasks of memory (β = -0.367, p = 0.023), attention (β = 0.428, p = 0.008) and executive functions (β = 0.326, p = 0.046). We found no significant difference in tests of language and spatial-temporal orientation (all p values > 0.05). Conclusions: SARS-CoV-2 infection was associated with cognitive impairment in memory, attention, and executive functions in older adults. Our findings are consistent with mechanistic evidence of the neurotropism of the virus and provide empirical support for the "Cognitive COVID" construct also in non-clinical samples. With nearly 800 million COVID-19 cases (in April 2023), and many more infections worldwide, the clinical and public health implications of Cognitive COVID due to SARS-CoV-2 infection may be massive and warrant further epidemiological investigations.

Indexed as

Cognitive COVIDCognitive declineLong COVIDNeuropsychological assessmentSARS-CoV-2 infectionSerological assessment

Identifiers

PMID38107020
PMCPMC10724488
OpenAlexW4388450632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.